Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization
Listen to oncology pharmacists, Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, discuss assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, providing their experiences using these therapies for their patients with early-stage breast cancer.
Decera Clinical Education Oncology Podcast · Julia L. Ziegengeist PharmD BCOP, Rodney Hunter PharmD BCOP
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, oncology pharmacists Julia L. Ziegengeist, PharmD, BCOP, and Rodney Hunter, PharmD, BCOP, explore and challenge common assumptions about adjuvant CDK4/6 inhibitor use in high-risk HR+/HER2- early breast cancer, offering insights on patient selection, trial nuances, toxicity management, and real-world decision-making.
Presenters:
Rodney Hunter, PharmD, BCOP
Director of Clinical Services
Memorial Hermann Texas Medical Center
Clinical Pharmacy Specialist
University of Texas Health Memorial Hermann Cancer Center
Professor
Texas Southern University College of Pharmacy and Health Sciences
Clinical Adjunct Professor
McGovern Medical School
Houston, Texas
Julia L. Ziegengeist, PharmD, BCOP
Clinical Pharmacist Specialist, Breast Medical Oncology
Levine Cancer, Atrium Health
Charlotte, North Carolina
Link to full program:
https://bit.ly/46SPGlU
Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.